

Monday 17 March 2025

Request under Freedom of Information Act 2000

Thank you for your request for information which we received on Tuesday 11 March 2025. I am pleased to confirm the following.

Q1. In the past 3 months, how many patients have received the following treatments (for any disease):

- | | |
|--|------------|
| • Berinert (Human C1-esterase inhibitor) | 0 patients |
| • Cinryze (Human C1-esterase inhibitor) | 0 patients |
| • Firazyr (Icatibant) | 0 patients |
| • Icatibant - any brand except Firazyr | 0 patients |
| • Orladeyo (Berotralstat) | 0 patients |
| • Ruconest (Recombinant human C1-esterase inhibitor) | 0 patients |
| • Takhzyro (Lanadelumab) | 0 patients |
| • Garadacimab (Andembry) | 0 patients |

Q2. In the past 3 months how many patients have received the following immunoglobulin treatments (for any disease):

- | | |
|-----------------------------------|-------------|
| • Cutaquig | 0 patients |
| • Cuvitru | 0 patients |
| • Gammagard | 0 patients |
| • Gammanorm | 0 patients |
| • Hizentra | 0 patients |
| • Hyqvia | 0 patients |
| • Intratect | 0 patients |
| • Iqymune | 0 patients |
| • Kiovig | 0 patients |
| • Privigen | 15 patients |
| • Octagam | 0 patients |
| • Panzyga | 0 patients |
| • Subgam | 0 patients |
| • Any other normal immunoglobulin | 0 patients |

If you are unhappy with the information received in response to this request, please address your complaint to the Patient Affairs Office at Milton Keynes Hospital NHS Foundation Trust, Standing Way, Eaglestone, Milton Keynes MK6 5LD. If, after exhausting our internal process, you are still unhappy with the information received, you may write to the Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

If you need any further assistance, please do not hesitate to contact us at the address above.

Yours sincerely

Freedom of Information Team Lead
For and on behalf of Milton Keynes Hospital NHS Foundation Trust

Any re-use of this information will be subject to the
'Re-use of Public Sector Information Regulations' and best practice.